Evidence-based policies: The case of breast cancer control in Colombia
DOI:
https://doi.org/10.35509/01239015.261Keywords:
Breast cancer, quality control, early detection, mammography, survivalAbstract
Colombia ranks at an intermediate risk level regarding the development of breast cancer, with an age-standardized incidence rate of 44.1 per 100,000 women. Although mammography screening and annual Clinical Breast Examination for women aged 50 to 69 are recommended in Colombia, as well as early detection for symptomatic women regardless of age, mortality from this cause has not been reduced in Colombia. Multiple causes seem to explain this problem: low participation of the target population in mammography screening activities, poor quality of mammography, and access barriers for timely diagnosis and comprehensive treatment. In view of this problem, the House of Representatives approved in first debate last October 3 Bill No. 259 of 2019 “by means of which measures and other provisions for prevention, diagnosis, timely treatment, rehabilitation, and palliative care of breast cancer are set up”. The Colombian National Cancer Institute INC, held a forum on December 9, 2019, aimed at reviewing the scientific support of the content of the bill and contribute to its proper discussion. The purpose of this paper is to present the analysis of the most controversial points from a scientific perspective, as a basis for appropriate decision-making in public health policy.
References
Bray, F. Transitions in Human Development and the Global Cancer Burden. In: Stewart BW, Wild C (Editors). World Cancer Report WHO, International Agency for Research on Cancer. Lyon: IARC Press; 2014.
Stewart BW, Wild C, WHO, International Agency for Research on Cancer. World Cancer Report 2014. Lyon: IARC Press; 2014.
Beau AB, Andersen PK, Vejborg I, Lynge E. Limitations in the Effect of Screening on Breast Cancer Mortality. J Clin Oncol. 2018;36(30):2988-94. https://doi.org/10.1200/JCO.2018.78.0270
IARC. Breast cancer Screening Group WHO, editor. Geneva: World Health Organization; 2016.
Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. New England Journal of Medicine. 2016;375(15):1438-47. https://doi.org/10.1056/NEJMoa1600249
Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women,2000-2012. JAMA. 2018;319(2):154-64. https://doi.org/10.1001/jama.2017.19130
Colombia, Ministerio de S, Instituto Nacional de C, Pardo Ramos C, Instituto Geográfico Agustín Codazzi. Atlas de mortalidad por cáncer en Colombia, 2017.
Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary Hormonal Contraception and the Risk of Breast Cancer. The New England journal of medicine. 2017;377(23):2228-39. https://doi.org/10.1056/NEJMoa1700732
Samson M, Porter N, Orekoya O, Hebert JR, Adams SA, Bennett CL, et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat. 2016;155(1):3-12. https://doi.org/10.1007/s10549-015-3663-1
Información de cáncer en Colombia [Internet]. Instituto Nacional de Cancerología. 2017. Disponible en: http://infocancer.co/portal/home.
Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud pública de Mexico. 2016;58:104-17. https://doi.org/10.21149/spm.v58i2.7779
Congreso Nacional de Chile. Ley No 19.966 del 03 de septiembre de 2004. Establece un Régimen de garantías explícitas en Salud.
Instituto Nacional de Cancerología Cancerología, Ministerio de Salud y Protección Social; Murillo R, Piñeros M, Wiesner C, Rivera D. Plan Decenal para el control del cáncer. Bogotá: INC; 2012.
Ministerio de Salud y Protección Social, Colciencias; Instituto Nacional de Cancerología, Fedesalud. Guía de práctica clínica (GPC) para la detección temprana, tratamiento integral, seguimiento y rehabilitación del cáncer de mama. Bogotá: Ministerio de Salud y Protección Social - Departamento Administrativo de Ciencia Tecnología e Innovación en Salud (COLCIENCIAS); 2013.
Congreso de la República. Proyecto de ley No 259 de 2019 Cámara Proyecto de Ley “Por medio de la cual se establecen medidas para la prevención, diagnóstico, tratamiento oportuno, rehabilitación, y cuidados paliativos del Cáncer de Mama y se dictan otras disposiciones”.
Pardo C, Cendales R. Incidencia, mortalidad y prevalencia en cáncer en Colombia 2007-2011. INC: Bogotá, 2015.
Instituto Nacional de Salud. Cáncer de mama y cuello uterino. Vigilancia epidemiológica Boletín Epidemiológico. Bogotá: Instituto Nacional de Salud; 2018.
Piñeros M, Znaor A, Mery L, Bray F. A Global Cancer Surveillance Framework Within Noncommunicable Disease Surveillance: Making the Case for Population-Based Cancer Registries. Epidemiologic Rev. 2017;39(1):161-9. https://doi.org/10.1093/epirev/mxx003
Colombia, Federación Colombiana de Enfermedades de Alto Costo. Situación del cáncer en la población atendida adulta en el SGSS en Colombia. Bogotá: Cuenta de Alto Costo; 2018.
Bray F, International Agency for Research on C, International Association of Cancer R, World Health O. Planning and developing population-based cancer registration in low-and middle-income settings, 2014.
European Commission. European Commission Initiative on Breast Cancer (ECIBC): European guidelines on breast cancer screening and diagnosis. JOINT RESEARCH CENTRE. 16 Oct 2019 [internet] [consultado el 30 abril de 2020]. Disponible en: https://healthcarequality.jrc.ec.europa.eu/sites/default/files/Guidelines/EtDs/ECIBC_GLs_EtD_screening_70-74.pdf
European Commission ECIBC recommendation on breast cancer screening ages, Bibliography. 15 Oct 2019 [internet] [consultado el 30 abril de 2020]. Disponible en: https://healthcarequality.jrc.ec.europa.eu/sites/default/files/Guidelines/Bibliographies/ECIBC_GLs_Bibliography_screening_ages.pdf
European Commission. European Commission Initiative on Breast Cancer (ECIBC): European guidelines on breast cancer screening and diagnosis, Evidence profile. JOINT RESEARCH CENTRE. 21 Oct 2019 [internet] [consultado el 30 abril de 2020]. Disponible en: https://healthcarequality.jrc.ec.europa.eu/sites/default/files/Guidelines/EvidenceProfiles/ECIBC_GLs_EP_screening_70-74.pdf
Hendrick RE. Obligate Overdiagnosis Due to Mammographic Screening: A Direct Estimate for U.S. Women. Radiology. 2018;287(2):391-7. https://doi.org/10.1148/radiol.2017171622
Herrmann C, Vounatsou P, Thurlimann B, Probst-Hensch N, Rothermundt C, Ess S. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ open. 2018;8(3):e017806. https://doi.org/10.1136/bmjopen-2017-017806
Asociación Probienestar de la Familia C, Ojeda G, Gómez López C, Martínez Gómez CL. Encuesta nacional de demografía y salud 2015. Bogotá; 2017.
Profamilia. Salud sexual y reproductiva en Colombia: resultados encuesta nacional de demografía y salud 2005. Bogotá: Profamilia; 2005.
Ojeda G, Ordóñez G M, Ochoa LH, Asociación Probienestar de la familia c, Macro I. Colombia Encuesta nacional de demografía y salud, 2010. [Bogotá]; Calverton (Md.), US: Asociación Probienestar de la Familia Colombiana, Profamilia; ORC Macro International; 2011.
Martínez HA, Wiesner C, Arciniegas-Álvarez MA, PovedaSuárez CA, Puerto-Jiménez DN, Ardila-Hernández IT, et al. La calidad de la mamografía en Colombia: análisis de un estudio piloto. Anales de Radiología México. 2013;3:164-74.
Martínez HA, Salazar-Hurtado EJ, Poveda-Suárez CA, Puerto-Jiménez DN, Ramírez-Campos F, Roldán-Sánchez OI. Impacto del programa de aseguramiento de la calidad de las mamografías en Colombia. Anales de Radiología México 2014;13(4).
Martínez HA, Salazar-Hurtado EJ, Puerto-Jiménez DN. Calidad de la imagen y dosis de radiación en mamografía en 10 ciudades de Colombia: resultados del control de calidad en 60 equipos mamográficos. Rev Colomb Cancerol. 2017;21(1). https://doi.org/10.1016/j.rccan.2017.02.035
Puerto DN, Martínez HA, Montoya LM, Rueda Y, César Poveda CA, Weisner C. Análisis de concordancia en la interpretación de imágenes mamográficas entre médicos radiólogos de Bogotá, D. C. Revista Medicina. 2018;40(2).
Geertse TD, Holland R, Timmers JM, Paap E, Pijnappel RM, Broeders MJ, et al. Value of audits in breast cancer
screening quality assurance programmes. European radiology. 2015;25(11):3338-47. https://doi.org/10.1007/s00330-015-3744-x
Roland H, Henny R, Jan H. The Dutch Population-Based Mammography Screening: 30-Year Experience. Breast Care. 2007;2:12-8. https://doi.org/10.1159/000099249
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 populationbased registries in 71 countries. Lancet. 2018;391(10125):1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed Initiation of Adjuvant Chemotherapy Among Patients with Breast Cancer. JAMA. 2016;2(3):322-9. https://doi.org/10.1001/jamaoncol.2015.3856
Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC cancer. 2011;11:131. https://doi.org/10.1186/1471-2407-11-131
Biganzoli L, Marotti L, Hart CD, Cataliotti L, Cutuli B, Kuhn T, et al. Quality indicators in breast cancer care: An update from the EUSOMA working group. Eur J Cancer. 2017;86:59-81. https://doi.org/10.1016/j.ejca.2017.08.017
Piñeros M, Sánchez R, Cendales R, Perry F, Ocampo R, Armando O. Características sociodemográficas, clínicas y de la atención de mujeres con cáncer de mama en Bogotá. Rev Colomb Cancerol. 2008;12(4):181-90G
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Revista Colombiana de Cancerología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los derechos reservados.
